ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Clinical trials for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEPATOCELLULAR CARCINOMA (HCC) trials appear
Sign up with your email to follow new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a new cell therapy called super Hi-TCR-T cells in 30 people with advanced liver cancer that has not responded to other treatments. The cells are designed to attack multiple targets on cancer cells. The goal is to see if the treatment is safe and can slow or stop …
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE1, PHASE2 • Sponsor: Eastern Hepatobiliary Surgery Hospital • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New drug combo shows promise for advanced liver cancer in early trial
Disease control Recruiting nowThis study tests a new treatment for advanced liver cancer that has spread. It combines an immunotherapy drug (adebrelimab) with chemotherapy and a targeted therapy (bevacizumab). The goal is to see if giving the immunotherapy directly into the liver's artery works better than th…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
Engineered immune cells take on advanced liver cancer in new trial
Disease control Recruiting nowThis early study tests a new treatment for advanced liver cancer that has not responded to standard therapies. It uses the patient's own immune cells, modified to target a protein called GPC3 found on cancer cells. The main goals are to check safety and find the right dose, while…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: NA • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New hope for liver cancer: drug cocktail targets tumors after immunotherapy fails
Disease control Recruiting nowThis study tests a new drug called WGI-0301 combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery. Participants must have already tried immunotherapy (PD-1/PD-L1 inhibitors). The goal is to find the safest dose and see if the combinatio…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
Engineered immune cells take on tough liver cancer
Disease control Recruiting nowThis study tests a new treatment for adults with advanced liver cancer that has stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor that are designed to target and kill cancer cells. The study will fir…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Super CAR-T takes on advanced liver cancer in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called Super CAR-T for people with advanced liver cancer that has not responded to other therapies. The treatment uses a patient's own immune cells, modified to target a protein (GPC3) found on liver cancer cells. The main goals are to…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE1 • Sponsor: Guangzhou FineImmune Biotechnology Co., LTD. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New combo attack on tough liver cancer: immunotherapy plus radiation
Disease control Recruiting nowThis study is for people with advanced liver cancer that has grown into major blood vessels. It tests whether adding a type of radiation (particle beam) to standard immunotherapy helps control the cancer longer. About 128 adults will take part. The goal is to see if the combinati…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Liver cancer immunotherapy showdown: which works best?
Knowledge-focused Recruiting nowThis study is watching 150 adults with advanced liver cancer who are starting immunotherapy for the first time. Researchers want to see how well different treatments shrink tumors and how the immune system changes. The goal is to learn which approach works best, not to test a new…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC